This technology identifies PAG as a cancer immunotherapy target and demonstrates the effectiveness of PAG inhibition using anti-PAG antibodies for tumor clearance.
Immune checkpoint inhibitors, such as anti-PD-1, are a relatively new modality that enhances anti-tumor immune responses in T cells of individuals with cancer. Despite great potential, the average response rate for PD-1 binding blockade for most tumors is low, requiring substantial improvement.
This technology identifies the PAG protein as a target for cancer immunotherapy and demonstrates the effectiveness of anti-PAG antibody treatment in a tumor-bearing animal model. PAG interactions regulate proper PD-1 signaling; as such, antibodies designed to inhibit PAG successfully prevent PAG/PD-1 interactions, increasing T cell activation, and limiting tumor growth in combination with immune checkpoint inhibitor treatment in mice. This technology has the potential to significantly reduce tumor burden either as a monotherapy or in combination with existing cancer therapies.
Patent Pending (WO/2024/098036)
IR CU23123
Licensing Contact: Cynthia Lang